151 related articles for article (PubMed ID: 25501233)
1. ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Zhang H; Li J; Zhang Y; Sun M; Zhao P; Zhang G; Jin C; Sun L; He M; Wang B; Zhang X
Genet Mol Res; 2014 Dec; 13(4):10215-22. PubMed ID: 25501233
[TBL] [Abstract][Full Text] [Related]
2. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zhao H; Zhang H; Du Y; Gu X
Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
[TBL] [Abstract][Full Text] [Related]
4. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
[TBL] [Abstract][Full Text] [Related]
7. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
9. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
[TBL] [Abstract][Full Text] [Related]
10. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR
J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416
[TBL] [Abstract][Full Text] [Related]
11. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Leng XF; Chen MW; Xian L; Dai L; Ma GY; Li MH
J Exp Clin Cancer Res; 2012 Mar; 31(1):25. PubMed ID: 22439756
[TBL] [Abstract][Full Text] [Related]
12. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
Wang X; Zhao J; Yang L; Mao L; An T; Bai H; Wang S; Liu X; Feng G; Wang J
Med Oncol; 2010 Jun; 27(2):484-90. PubMed ID: 19488864
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
[TBL] [Abstract][Full Text] [Related]
14. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
[TBL] [Abstract][Full Text] [Related]
15. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
17. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
Rosell R; Felip E; Taron M; Majo J; Mendez P; Sanchez-Ronco M; Queralt C; Sanchez JJ; Maestre J
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
[TBL] [Abstract][Full Text] [Related]
18. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G
J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Qin X; Yao W; Li W; Feng X; Huo X; Yang S; Zhao H; Gu X
Tumour Biol; 2014 May; 35(5):4697-704. PubMed ID: 24443257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]